Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

First Affiliated Hospital of Zhejiang University is the lead sponsor of 110 current clinical trials in our China register. 77 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Cytarabine, Venetoclax and Toripalimab. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Recruiting7770%
Not yet open2119%
Active, closed76%
By invitation55%

Trials by phase

Phase 23128%
Not applicable2926%
Observational2926%
Phase 376%
Phase 155%
Phase 1/244%
Phase 2/322%
Phase 422%
Phase EARLY_PHASE111%

Clinical trials sponsored by First Affiliated Hospital of Zhejiang University

110 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors NCT07692841 · Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor Drug: G-Csf	Phase 3	Recruiting	2026-07	China
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) NCT07285889 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease	Phase 1/2	Recruiting	2025-12	China
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes Drugs: Busulfan, Venetoclax	Not applicable	Recruiting	2025-08	China
Universal CNK-UT Therapy for Refractory aGVHD NCT06750133 · ClinicalTrials.gov ↗ · Acute Graft-versus-Host Disease	Phase 1	Recruiting	2024-12	China
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution NCT07034339 · ClinicalTrials.gov ↗ · Immune Evasion, Tumor, Pancreas Cancer	Observational	Recruiting	2025-05	China
The Peripheral Blood Multi-Omics Study on Sleep Loss NCT06492109 · ClinicalTrials.gov ↗ · Sleep Deprivation, Aging, Alzheimer Disease	Not applicable	Recruiting	2024-06	China
Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients NCT07162298 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2025-04	China
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not NCT06463717 · ClinicalTrials.gov ↗ · Multiple Myeloma, Minimal Residual Disease Drug: ASCT	Observational	Recruiting	2023-12	China
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia NCT07105579 · ClinicalTrials.gov ↗ · Leukemia, Relapse	Phase 2	Recruiting	2025-08	China
Safety and Efficacy of Eculizumab in High-risk TA-TMA NCT07707687 · ClinicalTrials.gov ↗ · Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Drug: Eculizumab	Phase 2	Recruiting	2026-07	China
18F-Pentixafor PET in Hematologic Malignancies NCT07122674 · ClinicalTrials.gov ↗ · Hematological Malignancies	Observational	Recruiting	2025-07	China
Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury NCT07735182 · ClinicalTrials.gov ↗ · Sepsis, Acute Kidney Injury Due to Sepsis, Gastrointestinal Microbiome	Observational	Recruiting	2026-02	China
Micro-movements in Patients With Prolonged Disorders of Consciousness NCT06406413 · ClinicalTrials.gov ↗ · Consciousness Disorders	Observational	Recruiting	2024-05	China
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial NCT07396480 · ClinicalTrials.gov ↗ · Venentoclax, Myeloid Malignancies, Conditioning Drugs: Fludarabine and Melphalan, Venetoclax	Phase 3	Recruiting	2026-03	China
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) NCT06611813 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer Drug: Toripalimab	Phase 2	Recruiting	2024-06	China
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway NCT05913960 · ClinicalTrials.gov ↗ · Major Depressive Disorder, Major Depressive Disorder, Recurrent	Not applicable	Recruiting	2023-02	China
Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder NCT06109337 · ClinicalTrials.gov ↗ · ADHD, Immune System, Clinical Syndrome	Observational	Recruiting	2023-12	China
Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease NCT06385106 · ClinicalTrials.gov ↗ · Alzheimer Disease	Not applicable	Recruiting	2024-03	China
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study. NCT06164561 · ClinicalTrials.gov ↗ · Myelofibrosis	Observational	Recruiting	2023-11	China
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma NCT06813742 · ClinicalTrials.gov ↗ · Pheochromocytoma Drug: 18F-MFBG	Observational	Recruiting	2023-05	China
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL NCT06361329 · ClinicalTrials.gov ↗ · ETP-ALL Drugs: Cyclophosphamide, Cytarabine, Daunorubicin	Phase 3	Recruiting	2024-04	China
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL NCT06554626 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia Drugs: Ara-C, Blinatumomab, Cytarabine	Phase 2	Recruiting	2024-08	China
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML NCT07172204 · ClinicalTrials.gov ↗ · Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60	Phase 2	Recruiting	2025-09	China
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) NCT06874933 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer Drug: Anlotinib and Benmelstobart	Phase 2	Recruiting	2025-05	China
The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy NCT07389083 · ClinicalTrials.gov ↗ · Hypoxia, Pulmonary Nodule, Pulmonary Infection	Not applicable	Recruiting	2025-12	China
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174 · ClinicalTrials.gov ↗ · Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer Drugs: 5-Fluorouracil/Leucovorin, Anlotinib, Gemcitabine/Cisplatin	Phase 2	Recruiting	2025-06	China
A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury NCT07050550 · ClinicalTrials.gov ↗ · Liver Injury	Observational	Recruiting	2024-12	China
AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer NCT07525765 · ClinicalTrials.gov ↗ · Gastrectomy for Gastric Cancer, Gastric Cancer	Observational	Recruiting	2026-04	China
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation NCT07003737 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B-precursor	Not applicable	Recruiting	2025-02	China
Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity NCT07589647 · ClinicalTrials.gov ↗ · Bipolar Disorder (BD)	Not applicable	Recruiting	2026-04	China
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy NCT07347990 · ClinicalTrials.gov ↗ · Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT) Drug: Iptacopan	Not applicable	Recruiting	2026-08	China
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer Drugs: ATRA, Toripalimab	Not applicable	Recruiting	2024-10	China
Multicenter Study to Evaluate the Effectiveness and Safety of Flow-Diverting Stents for Distal Intracranial Aneurysms NCT07376590 · ClinicalTrials.gov ↗ · Aneurysms	Observational	Recruiting	2026-01	China
Remimazolam for Bronchoscopy in High-Risk Patients NCT07395596 · ClinicalTrials.gov ↗ · Pulmonary Infection, Pulmonary Nodule, Phthisis Drug: Remimazolam	Phase 4	Recruiting	2026-02	China
MR Microstructural Imaging for Prostate Cancer Diagnosis NCT07249281 · ClinicalTrials.gov ↗ · Prostate Cancer, Diffusion MRI	Observational	Recruiting	2020-09	China
GMPA Versus PPI for Gastric Protection and aGVHD Risk NCT07791849 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplantation (HSCT), aGVHD, Infection Drug: Esomeprazole	Not applicable	Recruiting	2026-09	China
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT NCT07442513 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplantation, Thrombocytopenia	Phase 3	Recruiting	2025-12	China
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) NCT06504940 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma Drugs: Obinutuzumab, Orelabrutinib	Phase 2	Recruiting	2024-06	China
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 2	Recruiting	2025-01	China
Efficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression NCT07021508 · ClinicalTrials.gov ↗ · Bipolar Depression	Not applicable	Recruiting	2025-05	China
Eluvia DES for the Patients with Femoropopliteal Artery Lesions. NCT05522218 · ClinicalTrials.gov ↗ · Vascular Diseases, Stent Complication	Observational	Recruiting	2022-08	China
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. NCT04778839 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2021-03	China
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL NCT06742515 · ClinicalTrials.gov ↗ · Precursor B-Cell Acute Lymphoblastic Leukemia Drug: Blinatumomab	Phase 2	Recruiting	2024-10	China
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors NCT04933669 · ClinicalTrials.gov ↗ · Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant Drug: Imatinib	Phase 2	Recruiting	2021-09	China
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD NCT07794514 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD	Not applicable	Recruiting	2026-10	China
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma NCT06852807 · ClinicalTrials.gov ↗ · Neuroblastoma Drug: 18F-MFBG	Observational	Recruiting	2025-02	China
Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ NCT07640438 · ClinicalTrials.gov ↗ · Healthy Participants Study Drug: BY002	Phase 1	Recruiting	2026-06	China
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL NCT06754267 · ClinicalTrials.gov ↗ · Precursor B-Cell Acute Lymphoblastic Leukemia Drugs: Olverembatinib, Venetoclax	Phase 2	Recruiting	2024-12	China
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS NCT06046313 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drugs: Decitabine, Venclyxto	Phase 2	Recruiting	2023-10	China
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT NCT07321626 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment Drug: Romiplostim N01	Phase 1	Recruiting	2025-06	China
Remimazolam Besylate in Sedation of Postcardioperative Patients NCT06716840 · ClinicalTrials.gov ↗ · Remimazolam, Propofol, Sedation Drugs: Propofol, Remimazolam	Not applicable	Recruiting	2025-02	China
Effects of Opioid Drugs on Sleep and Emotion in Patients With Moderate to Severe Cancer Pain NCT07616648 · ClinicalTrials.gov ↗ · Moderate to Severe Cancer Pain	Observational	Recruiting	2026-04	China
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) NCT07383818 · ClinicalTrials.gov ↗ · HR Positive/HER2 Low Breast Cancer Drug: Toripalimab	Phase 2	Recruiting	2026-02	China
Chinese Longitudinal and Systematic Study of Bioplar Disorder NCT05480150 · ClinicalTrials.gov ↗ · Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic	Not applicable	Recruiting	2021-11	China
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD NCT07184853 · ClinicalTrials.gov ↗ · Graft vs Host Disease Drugs: Etanercept, Ruxolitinib	Not applicable	Recruiting	2025-09	China
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) NCT06977893 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer Drug: Toripalimab	Phase 3	Recruiting	2025-03	China
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) NCT06832904 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib	Phase 2	Recruiting	2024-12	China
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer NCT06572813 · ClinicalTrials.gov ↗ · Pancreas Cancer Drugs: Bortezomib, MFOLFIRINOX, Sintilimab	Phase 1/2	Recruiting	2024-11	China
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) NCT07351487 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Phase 2	Recruiting	2025-09	China
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study NCT06114784 · ClinicalTrials.gov ↗ · Severe Pneumonia	Observational	Recruiting	2023-09	China
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML NCT06621212 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy Drugs: Cytarabine, Mitoxantrone Hydrochloride Liposome, Venetoclax	Phase 2	Recruiting	2024-07	China
The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression NCT05607654 · ClinicalTrials.gov ↗ · Treatment-resistant Depression	Not applicable	Recruiting	2023-01	China
The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia NCT06867315 · ClinicalTrials.gov ↗ · Benign Prostatic Hyperplasia	Not applicable	Recruiting	2024-05	China
CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors NCT07423728 · ClinicalTrials.gov ↗ · Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization Drug: G-Csf	Not applicable	Recruiting	2026-03	China
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML NCT06621199 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Cytarabine, Mitoxantrone Hydrochloride Liposome, Venetoclax	Phase 2	Recruiting	2024-07	China
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia NCT07198867 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), CAR-T Cell Therapy	Phase 1	Recruiting	2025-09	China
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease NCT07153848 · ClinicalTrials.gov ↗ · Alzheimer Disease	Observational	Recruiting	2024-07	China
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting NCT04694248 · ClinicalTrials.gov ↗ · Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction Drugs: Aspirin, Rivaroxaban	Not applicable	Recruiting	2021-11	China
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors NCT07010523 · ClinicalTrials.gov ↗ · Mesothelin-positive Advanced Malignant Solid Tumors Drugs: Cyclophosphamide, Fludarabine	Not applicable	Recruiting	2024-10	China
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases NCT06850103 · ClinicalTrials.gov ↗ · Colorectal Carcinoma, Oligometastases, pMMR Drugs: CAPEOX/XELOX, Serplulimab	Phase 2	Recruiting	2025-04	China
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127 · ClinicalTrials.gov ↗ · HR-positive,HER2-negative Breast Cancer Drugs: Cyclophosphamide, Epirubicin, Nab-paclitaxel	Phase 2	Recruiting	2024-07	China
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) NCT06682195 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer Drug: Toripalimab	Phase 2	Recruiting	2024-10	China
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML NCT07259707 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia	Phase 2	Recruiting	2026-01	China
New-Generation GMA Laryngeal Mask Airway Versus Conventional Inflatable Laryngeal Mask Airway NCT07177586 · ClinicalTrials.gov ↗ · Supraglottic Airway Devices Position	Not applicable	Recruiting	2025-09	China
VHAG in Treating R/R T-ALL/LBL NCT06742463 · ClinicalTrials.gov ↗ · Acute T Lymphpblastic Leukemia/Lymphoma Drugs: Ara-C, Cytarabine, G-Csf	Phase 2	Recruiting	2024-12	China
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment NCT06445881 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Perioperative Complication	Phase 2	Recruiting	2024-06	China
Micro-expressions in Patients With Prolonged Disorders of Consciousness NCT06088628 · ClinicalTrials.gov ↗ · Consciousness Disorders	Observational	Recruiting	2022-09	China
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT NCT06861348 · Leukemia, Lymphocytic, Acute	Phase 2	Not yet open	2025-03	China
A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies NCT07554807 · ClinicalTrials.gov ↗ · Nutritional Deficiency, Gastrointestinal Cancers, Sarcopenia	Phase 3	Not yet open	2026-04	China
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer NCT07787338 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drug: Trastuzumab Rezetecan	Phase 2	Not yet open	2026-09	China
A Prospective Study of Discomfort Symptoms in Patients With Aortic Disease After Endovascular Intervention NCT07114185 · ClinicalTrials.gov ↗ · Aortic Aneurysm and Dissection	Observational	Not yet open	2026-01	China
Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer NCT07621562 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch Repair Drugs: Sintilimab, Tafolecimab	Phase 2	Not yet open	2026-06	China
The Efficacy and Safety of Task-state-based Temporal Interference Stimulation (TI) in the Treatment of Patients With Depression NCT06826469 · ClinicalTrials.gov ↗ · Major Depressive Disorder	Not applicable	Not yet open	2026-06	China
Stereotactic Aspiration of Brain Stem Hematoma NCT07300501 · ClinicalTrials.gov ↗ · Brain Stem Hematoma	Not applicable	Not yet open	2026-01	China
Efficacy and Mechanism of IPSRT for Bipolar II Disorder NCT07654348 · ClinicalTrials.gov ↗ · Bipolar Disorder II	Phase 2	Not yet open	2026-07	China
Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study NCT07086274 · ClinicalTrials.gov ↗ · Migraine, Transcranial Magnetic Stimulation Repetitive	Not applicable	Not yet open	2025-07	China
TMS for Improving Cognitive Function in Bipolar Disorder NCT07414147 · ClinicalTrials.gov ↗ · Bipolar Disorder (BD), Cognitive Impairment	Not applicable	Not yet open	2026-03	China
18F-S2P PET Imaging in the Evaluation of Large Artery Atherosclerosis NCT07815860 · ClinicalTrials.gov ↗ · Large-Artery Atherosclerosis (Embolus/Thrombosis)	Not applicable	Not yet open	2026-09	China
18F-FAPI PET/CT and MRI in Gastric Cancer NCT07510867 · ClinicalTrials.gov ↗ · Gastric Cancer	Observational	Not yet open	2026-05	China
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease NCT07667517 · ClinicalTrials.gov ↗ · Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases Drug: Finerenone	Phase 4	Not yet open	2026-07	China
A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir NCT07577986 · ClinicalTrials.gov ↗ · HIV (Human Immunodeficiency Virus) Drug: Chidamide	Phase 1/2	Not yet open	2026-05	China
Effects of Precise Education on Postoperative Discomfort Symptoms in Patients With Aortic Disease Undergoing Endovascular Intervention: a Single-center Randomized Controlled Study NCT07362901 · ClinicalTrials.gov ↗ · Aortic Dissection Aneurysm, Aortic Dissection Rupture, Aortic Dissection Involving the Descending Thoracic Aorta	Observational	Not yet open	2026-01	China
Prediction of Stroke Risk in Patients with Atrial Fibrillation Based on Chest CT Images NCT06611995 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Ischemic Stroke	Observational	Not yet open	2024-09	China
18F-FAPI PET in Lung Cancer NCT07370805 · ClinicalTrials.gov ↗ · Lung Cancer (Diagnosis)	Observational	Not yet open	2026-02	China
18F-FAPI PET in Cancers of Unknown Primary Site NCT07372963 · ClinicalTrials.gov ↗ · Cancer of Unknown Primary Site	Observational	Not yet open	2026-02	China
A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota NCT07718503 · ClinicalTrials.gov ↗ · Retinal Vein Occlusion	Not applicable	Not yet open	2026-06	China
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. NCT06786299 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia(AML)	Phase EARLY_PHASE1	Not yet open	2025-02	China
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07159906 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Drugs: Homoharringtonine, Lisaftoclax, Prednisone	Phase 1/2	Not yet open	2025-09	China
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy NCT07651176 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Lisaftoclax Drugs: Aclarubicin, Azacitidine, Cytarabine	Phase 2/3	By invitation	2026-03	China
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy NCT07651163 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Lisaftoclax Drugs: Aclarubicin, Azacitidine, Cytarabine	Phase 2/3	By invitation	2026-03	China

Showing the 100 most recently updated of 110 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in First Affiliated Hospital of Zhejiang University trials

61 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 21 more in the trial list above.

Conditions in First Affiliated Hospital of Zhejiang University trials

169 conditions

Acute Myeloid Leukemia6 Alzheimer Disease3 HR+/HER2- Breast Cancer3 Major Depressive Disorder3Hematopoietic Stem Cell Transplantation (HSCT)3Myelodysplastic Syndromes2 Pancreas Cancer2 HER2-positive Breast Cancer2 Leukemia2Consciousness Disorders2Myelofibrosis2Pulmonary Nodule2Pulmonary Infection2Gastric Cancer2Lisaftoclax2Bipolar Disorder (BD)2Acute Myeloid Leukemia (AML)2Precursor B-Cell Acute Lymphoblastic Leukemia2Leukemia, Lymphocytic, Acute1Healthy Hematopoietic Stem Cell Donor1Healthy Allogeneic Hematopoietic Stem Cell Donor1Acute Graft Versus Host Disease1Nutritional Deficiency1Gastrointestinal Cancers1

By trial register

Register	Trials	Recruiting
Clinical trials in China	110	77

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
The First Affiliated Hospital of Soochow University	14
Taiho Oncology	5
Peking University People's Hospital	5
Zhejiang University	5
Shenzhen Geno-Immune Medical Institute	4
Stichting Hemato-Oncologie voor Volwassenen Nederland	3
Orca Biosystems	3
Shanghai Jiao Tong University School of Medicine	3
Kura Oncology	2
Shenzhen University General Hospital	2

Sponsors with the most current trials registered for this condition.

Questions about First Affiliated Hospital of Zhejiang University trials

How many clinical trials does First Affiliated Hospital of Zhejiang University sponsor?

First Affiliated Hospital of Zhejiang University is the lead sponsor of 110 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First Affiliated Hospital of Zhejiang University trials recruiting?

Yes. 77 of its 110 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First Affiliated Hospital of Zhejiang University testing?

Its current trials name 61 drugs and biologicals as interventions. The most frequent are Cytarabine (8), Venetoclax (8), Toripalimab (6), Homoharringtonine (5) and Cyclophosphamide (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

First Affiliated Hospital of Zhejiang University clinical trials